9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Pleural Mesothelioma Malignant Advanced

Estimated Enrollment: 320

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Progression-free Survival (PFS) according to the mRECIST v1.1,  Overall Survival (OS),  Overall Response (OR), Disease Control (DC) at 24 weeks

Interventions: Carboplatin, Pemetrexed

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: October 31, 2024

Completion Date: December 31, 2024

Last  Posted Date: June 25, 2019

Location: University Hospital Leuven, Leuven, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT03762018

Was this article helpful?
Dislike 0